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ABSTRACT

Bis(5-aminofluorescein)dichloroplatinum(II), and substituted fluoresceinamine derivatives of this compound
are disclosed as highly effective radiation sensitizers
which enhance the effect of ionizing radiation on tumor
cells, but uniquely do so without the usual accompanying high toxicity level to surrounding normal cells. A
direct combination, single step reaction synthesis is
disclosed for preparing bis(5-aminofluorescein)dichloroplatinum(II) from the reaction between an alkali
metal tetrachloroplatinate(II) and 5-aminofluorescein.
1 Claim, 3 Drawing Figures
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LOW TOXICITY RADIATION SENSITIZER
BACKGROUND OF THE INVENTION
5

In addition to being used in cancer chemotherapy,
cisplatin is also known as a radiation sensitizer. That is,
such that the cisplatin enhances the effect of ionizing
radiation on malignant tumors in order to improve local
and regional cancer treatment by radiation, see, for
10
example, Overgaard, et al., Cancer Treatment Reports
Vol. 65, Nos. 5-6, May/June, 1981, p. 501-503, which is
incorporated herein by reference. There, it is reported
that cisplatin will enhance the radiation response in
tumors by a factor of between 1.2 and I. 7 times the 15
effectiveness if no cisplatin is used. The report goes on
to describe the use of cisplatin as a marked and selective
enhancement of radiation's effects in solid tumors. Cisplatin has the formula:
20
Cl

"

NH3

Pt /

Cl /

"

NH3

25
The technical chemical name for cisplatin is cisdiaminedichloroplatinum(II). It is a square planar molecule and its effectiveness in biological systems is believed to be related to its configuration. The compound
was recognized for its biological significance in the
I 960's and its radiation sensitizing properties were demonstrated in the mid- l 970's.
While cisplatin per se has been known as an effective
radiation sensitizer, it does have problems which have
inhibited its practical use. The primary problem is its
high level of toxicity to normal living cells. Thus, while
it may successfully sensitize a carcinoma, making it
highly susceptible to radiation treatment, it also is quite
toxic to the surrounding normal cells. There is, therefore, a real and continuing need to develop a radiation
sensitizer which is at least equally as effective as cisplatin with respect to the enhancement of sensitivity of
carcinomas to radiation, but which will allow such
sensitization without being toxic to surrounding normal
living cells.
Needless to say, if one could develop a radiation
sensitizer of high level sensitizing effect, but with minimal toxicity to surrounding normal living cells, the net
effect would be that smaller doses of radiation could be
used to give the effect now achieved with only larger
radiation doses and thus, the total body exposure to
radiation reduced. Alternatively, for a given radiation
dose, its effectiveness could be increased without fear of
causing high level toxicity to surrounding normal tissue
cells.
It is a primary objective of the present invention to
provide a radiation sensitizer which is at least equal to
cisplatin in selective enhancement of radiation response,
but which provides such radiation response with a
much, much lower toxicity level to normal live cells.
An additional objective of the present invention is to
provide a radiation sensitizer which is at least equal to
cisplatin in enhancement of radiation response, but
which is several times less toxic than cisplatin to normal
living cells.
A further objective of this invention is to provide a
radiation sensitizer which is at least equal to cisplatin in

30

35
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radiation sensitization effect, but which is estimated to
be up to ten times less toxic to normal cells.
Another object is to provide a compound which like
cisplatin itself has antineoplastic properties.
A still further objective of the present invention is to
provide a molecular tracer which is fluorescent, thus
providing a unique and highly effective biological
tracer which is capable of binding to DNA nucleotides,
proteins, and lipids.
Yet another objective of this invention is to provide a
fluorescent biological tracer which also will function as
an effective biological stain for use in electron microscopy and fluorescence microscopy.
Still another objective of the present invention is to
provide a radiation sensitizer that has stability and solubility properties which make the compounds easy to
administer in dosage quantity.
And another objective of the present invention is to
provide a radiation sensitizer which is soluble in water
and soluble in common universal solvents such as dimethylsulfoxide, methyl alcohol, ethyl alcohol, acetone, etc.
Another very important objective of the present invention is to provide a highly effective, single step synthesis for production of fluorescently labeled cisplatin
type compounds, which do not employ cisplatin at all in
the synthesis procedure, but instead employ readily
available compounds in a single step, direct combination synthesis.
The method and manner of accomplishing each of the
above objectives, as well as others, will become apparent from the detailed description of the invention which
follows hereinafter.
SUMMARY OF THE INVENTION

40

This invention relates to cisplatin type fluorescently
labeled compounds which are effective radiation sensitizers. In particular, the compounds are bis(5-aminofluorescein)-dichloroplatinum(II) (abbreviated cis45 CFP) or certain substituted analogs thereof. They are
equal to cisplatin from the standpoint of their radiation
sensitivity enhancement, but are up to ten times less
toxic to normal living cells than cisplatin. In addition,
the compounds are highly effective, fluorescent biologi50 cal tracers. The invention also relates to a unique, single
step synthesis for preparing fluorescently labeled cisplatin type compounds, without ever employing cisplatin
in the synthesis route. As a result, the synthesis involves
55 a platinum salt and a relatively non-toxic 5-aminofluorescein, which are readily available.
BRIEF DESCRIPTION OF THE DRAWINGS
60

65

The drawings are graphs illustrating the good radiation sensitizing properties of the compounds of this
invention, coupled with their low toxicity level compared to cisplatin.
DETAILED DESCRIPTION OF THE
INVENTION
The compounds of this invention have the following
formula:
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R-0

wherein "X" is a halide and R and R' are selected from
the group consisting of hydrogen, C1 to C12 alkyl, C1 to 20
C12 alkenyl, C1 to C12 alkynyl, and aryl. Preferably "X"
is a chloride or bromide, and most preferably chloride.
It is preferred that R and R' be selected from the group
consisting of C1 to C6 alkyl, alkenyl, alkynyl, and aryl.
Most preferably, both R and R' are hydrogen.
25
The very most preferred compound of the invention
is bis(5-aminofluorescein)dichloroplatinum(II).
The compounds of the present invention can be
thought of as fluorescein derivatives of cisplatin.
Cisplatin has been known for several decades but has
only become biologically important since about the 30
mid-1960's. It is a square planar molecule known to
have adverse properties to normal, but especially to
neoplastic cells. It is also known as an effective radiation sensitizer. The term "radiation sensitizer" refers to
enhancement of the effect of ionizing radiation on cells, 35
most typically malignant cells in order to improve local
and regional cancer treatments. Cisplatin selectively
sensitizes and enhances the effective radiation response
in malignant growths with a lesser effect in normal
tissues. Thus, cisplatin has been accorded some high 40
level interest, because of its potential use in chemotherapy. However, one primary disadvantage with cisplatin
is that it has a high level of toxicity to normal tissue
cells.
Surprisingly, and contrary to the expectations in 45
working with cisplatin per se, the fluorescein derivatives of this invention are equal to cisplatin as radiation
sensitizers, but, contrary to cisplatin, have a very low
level toxicity to surrounding tissue cells. In fact, data
developed to date, reveal a toxicity level up to as much 50
as ten times lower than cisplatin. As a result, the compounds of this invention, and particularly the most preferred compound bis(5-aminofluorescein)dichloroplatinum(II), can be used as a much more effective
radiation sensitizer than cisplatin. In particular, since 55
the aminofluorescein derivative has a low toxicity level,
larger quantitites can be used in dosage treatments. As a
result, successful radiation treatments can occur with
much smaller radiation doses, resulting in overall reduced body exposure to radiation. Then too, large doses 60
of the radiation sensitizer can be used, increasing the
radiation sensitization effect, without any significant
worry of the high level toxicity to normal cells. In
particular, toxicity levels of the most preferred compound of this invention are up to ten times less than 65
cisplatin.
The compounds of the present invention are also
useful as biological tracers, since they are both fluores-

4

cent and have high binding capabilities to nucleic acids,
proteins and lipids. Prior to the development of the
compounds of this invention, it is not believed that there
has been·a biological tracer which is both fluorescent
and also offers binding properties similar to that of
cisplatin in that it may bind to nucleic acids, proteins
and lipids, and thus be easily traceable. This fluorescent
property, coupled with the binding ability to biologically important compounds, allows for fluorescent Iabeling of cells in biological work.
While the compounds discussed have been referred
to as platinum compounds, it is possible that other compounds can be made employing as the metal atom, any
of the metals of the platinum metal series, that is, rubidium, rhodium, palladium, osmium, irridium, and platinum. It is therefore contemplated as still within the
scope of this invention if the central metal atom of the
platinum compounds is replaced with other of the referred to metals of the platinum metal series.
Another highly important feature and advantage of
the compounds of the present invention is that they
have stability and solubility characteristics which make
them easy to work with from the standpoint of dosage
units. That is to say, they are soluble in water, they are
relatively stable, and they will dissolve in many universally employed solvents such as dimethylsulfoxide,
methanol, ethanol and acetone.
A surprisingly simple and straightforward single step
reaction synthesis has been developed for producing the
compounds of this invention. The method is surprising
because one would normally expect cisplatin per se to
be the starting material, since the compounds are derivatives of cisplatin. However, cisplatin is not involved in
the reaction at all. And yet, the compound which is
produced has all of the radiation sensitivity properties
of cisplatin. In accordance with the process of this invention, 5-aminofluorescein (Isomer I), or a substituted
5-aminofluorescein, is reacted with an alkali metal tetrachloroplatinate(II) in a single step, direct combination
synthesis: 5-aminofluorescein (Isomer I) has the formula:

HO

The alkali metal tetrachloroplatinate(II) is preferably
potassium tetrachloroplatinate(II) of the formula
K2[PtCl4). In the preferred methodology, an aqueous
solution of potassium tetrachloroplatinate(II) is mixed
with a hot methanol solution of 5-aminofluorescein,
with the molar ratio of potassium tetrachloroplatinate(II) to 5-aminofluorescein being 1:2. The solutions are mixed and the mixture is heated (with evaporation) at a slightly elevated temperature, perhaps 60° C.
After cooling to room temperature, a brown precipitate
forms which can be separated and recrystallized.
The following examples are offered to further illustrate, but not limit, the invention. It is understood that
modifications may be made in the illustrated examples.

5
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TABLE 1

EXAMPLES
Preparation of bis(5-aminofluorescein)dichloroplatinum(II) was accomplished using direct combination of an aqueous solution of potassium tetrachloroplatinate(II) and 5-aminofluorescein. In particular 0.415
grams of K1[PtCl4) in 25 milliliters of water was added
to 0.694 grams of 5-aminofluorescein in 50 milliliters of
boiling methanol. They were mixed, and the solution
was kept at about 60° C. for one hour. Thereafter, it was
allowed to cool, at which point a brown precipitate was
observed. The precipitating compound was filtered,
washing a little with absolute ethanol, and then with
diethyl ether. The brown compound remained. It
weighed 0.4 grams.
The reaction process was run again, exactly as described above, and gave a brown solid of 0.5 grams.
Nuclear magnetics resonance (NMR) testing, infrared (IR) analysis, visible-UV spectroscopy, and quantitative, elemental analysis all confirmed the presence of
bis(5-aminofluorescein)dichloroplatinum(II). In these
runs, the starting platinum compound came from the
Alpha Division of Ventron Corporation, and the starting 5-aminofluorescein compound came from Sigma
Chemical in St. Louis. Of course, other convenient and
suitable sources for the starting materials may be utilized.
Numerous repetitions of the synthesis procedure
shown here, have occurred and all upon various analysis techniques mentioned herein confirm the presence of
bis 5-aminofluorescein) dichloroplatinum(II).
The process was repeated using as the starting material K2[PtBr4) and the resulting product was bis (5aminofluorescein) dibromoplatinum(II).
The bis(5-aminofluorescein)dichloroplatinum(II) prepared in the manner previously described herein, was
tested for effectiveness as a radiation sensitizer. In particular, the compound was complexed with nucleotides
in vitro. The stability of the compound was studied in a
buffered saline solution over a period of time. Finally,
the cell growth effects of the compound from the standpoint of its effects on living cells were studied, as described below.
The drawings illustrate the effective nature of the
compounds of this invention as radiation sensitizers, and
compare the toxicity level of the compounds of this
invention with the toxicity level of cisplatin from the
standpoint of their effects on living cells.
FIG. 1 shows the effectiveness of the compound of
this invention, in particular bis(5-aminofluorescein)dichloroplatinum (II) in terms of its effectiveness as a
·radiation sensitizer. In particular, in looking at FIG. 1,
the "x" axis shows radiation dose as measured in kilorads (krad). The "y" axis shows the surviving fraction
of bacterial cells (S. typhimurium Tm 677). The line
represented by black dots and dashes shows the effect of
radiation alone on this bacterial system under a nitrogen
blanket. This simulates anaerobic conditions in vivo.
The lines showing squares with dashes and pluses with
dashes shows the decrease in survival produced by 20
µm and 100 µm cis-CFP respectively over a range of
radiation dosages. The radiosensitization produced by
cis-CFP exhibits a dose dependent effect. It also exhibits
a much reduced toxicity as compared to equamolar
concentrations of cisplatin; this makes it difficult to
make direct comparisons. Studies using the S. typhimurium Tm 677 bacterial system produce the following
data.

Toxicity after
~ hour at room
Concentration of temperature [no
radiation survival]
Compound

5
Cisplatin
cis-CFP

100 µ.M
100 µ.M

10%
100% survival

Radiation
Enhancement
Ratio

2A
1.6

10 Even though the enhancement of the 100 µM concentration is less for cis-CFP than for displatin, the extreme
differences in toxicity demonstrate the utility of cisCFP as compared to cisplatin.
Though difficult to compare directly, other work
15 using mice to study cisplatin-induced radiosensitization
shows a radiation enhancement ratio of up to 1.7. This
is comparable to the 1.6 value demonstrated for cis-CFP
in the bacterial system.
Also, cisplatin under nitrogen is an assay using E. coli
20
exposed to 5X IQ-5 M cisplatin shows an enhancement
ratio of about 1.77. It therefore can be seen that although direct comparison is difficult, they are comparable in radiation sensitizing ability.
25
FIG. 2 shows the growth of a culture of Tetrahymena in a nutrient medium which comprises 2% by
weight of proteose peptone, 0.1 % by weight sodium
hydrogen phosphate, 0.1 % sodium acetate and with the
balance being distilled water. The "x" axis shows cul30
ture growth in time with the "y" axis indicating media
density, an indication of cell numbers. As can be seen,
the greatest cell growth is exhibited in the control,
which are free living and growing protozoan cells in the
35 presence of a nutrient. The toxicity of cisplatin when
added to the control solution at a concentration of IQ-5
molar is also shown. The toxicity of the compounds of
this invention at IQ-4molar and IQ-5 molar concentrations are likewise shown. It can be seen that the level of
40 toxicity compounds of the present invention is much,
much less at a given molar concentration than is cisplatin. This is further illustrated in FIG. 3, which shows
the same free living protozoan cell Tetrahymena, but
shows its motility rate declining in the presence of cis45
platin and a compound of the invention. Cisplatin is the
dotted line and the compound of the invention is the
solid line. There, the "x" axis measures time of exposure
with the "y" axis measuring the motility rate of the
so organisms. The steeper the line indicating the mobility
of the organism, the more toxic the compound. There,
the concentration in both instances of cisplatin and the
compound of the invention was 2X I0-3 molar. It can
be seen that at any given time, the mobility is much
55 more reduced by cisplatin than the compound of this
invention, indicating a much higher toxicity level of
cisplatin.
It therefore can be seen that the compounds of the
present invention are substantially equal in radiation
60
sensitizing effect to cisplatin, but that they are up to as
many as ten times less toxic to normal living cells, see
FIGS. 2 and 3 and the data presented therein.
Thus, the invention accomplishes at least all of its
65 stated objectives.
What is claimed is:
1. Bis(5-aminofluorescein)dichloroplatinum(II) of the
formula:

7
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